Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA6 | P23280 | 2/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20109700 | 0.83 | GAA (0.39) | TDP1GAAERN1ALDH1A1MCL1 | |
| SCHEMBL29098887 | 0.82 | TDP1 (0.48) | TDP1GAAERN1ALDH1A1CA1 | |
| SCHEMBL7892856 | 0.76 | GAA (0.50) | TDP1GAAERN1ALDH1A1CA1 | |
| SCHEMBL10291568 | 0.75 | GRIA1 (0.41) | ERN1ALDH1A1MCL1CA1CA2 | |
| SCHEMBL17049150 | 0.75 | TDP1 (0.42) | TDP1GAAERN1ALDH1A1CA1 | |
| SCHEMBL13448073 | 0.75 | ERN1 (0.48) | TDP1ERN1ALDH1A1CYP3A4 | |
| SCHEMBL2766461 | 0.74 | GAA (0.53) | TDP1GAAALDH1A1CA1CA2 | |
| SCHEMBL3134002 | 0.74 | TDP1 (0.59) | TDP1ERN1ALDH1A1CYP3A4 | |
| SCHEMBL2307383 | 0.73 | GAA (0.46) | TDP1GAAERN1ALDH1A1CA1 | |
| SCHEMBL18133931 | 0.72 | TDP1 (0.43) | TDP1ERN1ALDH1A1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-119301127-A | 6-Oxo-decahydro pyrrolo [1,2-a ] [1,5] diazocine and 6-oxo-decahydro-4H-pyrrolo [2,1-d ] [1,5] thiaazacine derivatives as modulators of STAT3 and STAT6 for the treatment of cancer and inflammatory conditions | 瑞克鲁迪克斯制药股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-10150787-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-12-11 | — | — | US | disclosed |
| US-20180265531-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2018-09-20 | — | — | US | disclosed |
| US-10005804-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2018-06-26 | — | — | US | disclosed |
| US-10005804-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2018-06-26 | — | — | US | disclosed |
| US-10005804-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2018-06-26 | — | — | US | disclosed |
| US-20180072763-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2018-03-15 | — | — | US | disclosed |
| US-20180072763-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2018-03-15 | — | — | US | disclosed |
| US-20180072763-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV (CA) | 2018-03-15 | — | — | US | disclosed |
| US-9828399-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-11-28 | — | — | US | disclosed |
| US-9828399-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-11-28 | — | — | US | disclosed |
| US-9828399-B2 | TC-PTP inhibitors as APC activators for immunotherapy | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-11-28 | — | — | US | disclosed |
| US-20170015690-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2017-01-19 | — | — | US | disclosed |
| US-20170015690-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2017-01-19 | — | — | US | disclosed |
| US-20170015690-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2017-01-19 | — | — | US | disclosed |
| EP-3110824-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127548-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005804-B2 | TC-PTP inhibitors as APC activators for immunotherapy | PTPRCAP, PTPRC, PTPA | TDP1 1721/4885GAA 373/4885ERN1 3896/4885 |
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | STAT6, STAT3, STAT1 | TDP1 2910/4885GAA 4278/4885ERN1 3432/4885 |
| US-20170015690-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | PTPRCAP, PTPRC, PTPA | TDP1 1721/4885GAA 373/4885ERN1 3896/4885 |
| US-20180265531-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | PTPRCAP, PTPRC, PTPA | TDP1 1721/4885GAA 373/4885ERN1 3896/4885 |
| US-20180072763-A1 | TC-PTP INHIBITORS AS APC ACTIVATORS FOR IMMUNOTHERAPY | PTPRCAP, PTPRC, PTPA | TDP1 1721/4885GAA 373/4885ERN1 3896/4885 |
| US-10150787-B2 | TC-PTP inhibitors as APC activators for immunotherapy | PTPRCAP, PTPRC, PTPA | TDP1 1721/4885GAA 373/4885ERN1 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.